Source: Publicity Department of Suzhou High-tech Development Zone (Huqiu District)
Recently, Suzhou magAssist Medical Technology Co., Ltd. (“magAssist”) and Zhongshan Hospital, Fudan University (“Zhongshan Hospital”) entered into a cooperation agreement on the interventional VAD project. The clinical expert team led by Junbo GE, academician of the Chinese Academy of Sciences, Director of Shanghai Institute of Cardiovascular Diseases and Director of the Department of Cardiology, Zhongshan Hospital, will work with magAssist R&D team to jointly develop the interventional VAD project.
At the cooperation initiation conference, both parties introduced their respective team. magAssist R&D engineer team demonstrated the principled prototype; Mr. GE and his clinical expert team put forward key suggestions for clinical application scenarios on the VAD R&D technical plan. The clinical indicators, design goals and R&D plan were also specified in the conference.
There are more than 1 million coronary interventional operations performed in China every year. With the progress of society and the trend of aging population, the number of operations is growing year by year, and the patients’ conditions are increasingly complex. An interventional circulatory assist device can insert a miniaturized blood pump into the aorta through peripheral vascular interventional surgery, so as to provide rapid and non-invasive circulatory support in the event of heart pump failure. For intraoperative cardiac protection during high-risk coronary interventions, as well as for patients with cardiogenic shock caused by acute myocardial infarction, it is undoubtedly a strong line of defense in front of death, and the most challenging technology among all cardiovascular interventional devices.
“Zhongshan Hospital represents the top level of cardiology in China. Under the leadership of Mr. GE, the expert team of Zhongshan Hospital has been constantly challenging the technical peak in coronary intervention for the benefit of patients,” Dr. Po-Lin HSU, founder and CEO of magAssist, said. Through the integration of medical and engineering advantages, magAssist and Zhongshan Hospital will strive to overcome the “last mile” difficulty of cardiovascular interventional therapy, and jointly develop domestically made high-end medical devices for the vast number of patients with cardiovascular diseases in China and in the world at large. The interventional VAD under development is expected to be put into clinical trials in 2022.
Founded in Suzhou Science and Technology Town in 2017, magAssist is located in Jiangsu MedPark. On the basis of core platform technologies like mechatronics, maglev and computational fluid mechanics, magAssist has developed high-end medical devices centered on extracorporeal life support comparable to or surpassing imported products, including interventional artificial heart and new-generation ECMO based on maglev extracorporeal artificial heart technology.
Currently magAssist has established an office/R&D laboratory about 700 m2. Compliant with ISO13485/GMP and Class 10,000 Cleanroom Requirements, the 1700-m2 maglev extracorporeal artificial heart production line of magAssist, first of its kind in China, can accommodate three assembly and production lines of high value consumables as well as active equipment.
It’s understood that magAssist’s fist product—the short and medium-term extracorporeal artificial heart will be put into clinical trials at the end of 2020. Another product, the new-generation ECMO, is expected to be put into clinical trials in 2022. “magAssist will continuously complete its product layout based on the goal of covering the clinical needs of extracorporeal life support for critically ill patients, develop platform-based solutions of emergency and critical ECLS systems for different groups of people, different auxiliary needs and different clinical scenarios, and serve patients all over the world as soon as possible,” Dr. Po-Lin HSU revealed. (Ke)